Is tenofovir disoproxil fumarate superior to entecavir for prevention of hepatocellular carcinoma in patients with chronic hepatitis B?
作者信息
van Velsen Lisa M, Sonneveld Milan J, van Erpecum Karel J
机构信息
Department of Gastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam, The Netherlands.
Department of Gastroenterology and Hepatology, University Medical Center Utrecht, Utrecht, The Netherlands.
出版信息
Hepatobiliary Surg Nutr. 2023 Dec 1;12(6):919-922. doi: 10.21037/hbsn-23-472. Epub 2023 Nov 15.
Abstract
摘要
相似文献
1
Is tenofovir disoproxil fumarate superior to entecavir for prevention of hepatocellular carcinoma in patients with chronic hepatitis B?
Hepatobiliary Surg Nutr. 2023 Dec 1;12(6):919-922. doi: 10.21037/hbsn-23-472. Epub 2023 Nov 15.
2
Hepatocellular carcinoma risk in patients with chronic hepatitis B receiving tenofovir- vs. entecavir-based regimens: Individual patient data meta-analysis.
J Hepatol. 2023 Mar;78(3):534-542. doi: 10.1016/j.jhep.2022.12.007. Epub 2022 Dec 23.
3
Risk of Hepatocellular Carcinoma in Patients Treated With Entecavir vs Tenofovir for Chronic Hepatitis B: A Korean Nationwide Cohort Study.
JAMA Oncol. 2019 Jan 1;5(1):30-36. doi: 10.1001/jamaoncol.2018.4070.
4
Efficacy of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide in treatment-naive hepatitis B patients.
Hepatol Int. 2021 Dec;15(6):1328-1336. doi: 10.1007/s12072-021-10262-y. Epub 2021 Nov 20.
5
No difference in hepatocellular carcinoma risk in chronic hepatitis B patients treated with tenofovir vs entecavir: evidence from an updated meta-analysis.
Aging (Albany NY). 2021 Feb 26;13(5):7147-7165. doi: 10.18632/aging.202573.
6
Long-term entecavir or tenofovir disoproxil fumarate therapy in treatment-naïve chronic hepatitis B patients in the real-world setting.
J Viral Hepat. 2015 May;22(5):504-10. doi: 10.1111/jvh.12358. Epub 2014 Nov 28.
7
Tenofovir is Superior to Entecavir in Patients with Treatment-naïve Hepatitis B e-Antigen-Positive Chronic Hepatitis B.
J Clin Exp Hepatol. 2021 Jan-Feb;11(1):37-44. doi: 10.1016/j.jceh.2020.05.003. Epub 2020 May 19.
8
A multicenter study of entecavir vs. tenofovir on prognosis of treatment-naïve chronic hepatitis B in South Korea.
J Hepatol. 2019 Sep;71(3):456-464. doi: 10.1016/j.jhep.2019.03.028. Epub 2019 Apr 6.
9
Lower risk of hepatocellular carcinoma with tenofovir than entecavir in antiviral treatment-naïve chronic hepatitis B patients: a systematic review and meta-analysis involving 90,897 participants.
Clin Exp Med. 2023 Oct;23(6):2131-2140. doi: 10.1007/s10238-023-00990-w. Epub 2023 Jan 17.
10
Magnitude of and prediction for risk of hepatocellular carcinoma in patients with chronic hepatitis B taking entecavir or tenofovir therapy: A systematic review.
J Gastroenterol Hepatol. 2020 Oct;35(10):1684-1693. doi: 10.1111/jgh.15078. Epub 2020 May 17.
本文引用的文献
1
Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study.
Lancet Gastroenterol Hepatol. 2023 Oct;8(10):879-907. doi: 10.1016/S2468-1253(23)00197-8. Epub 2023 Jul 27.
2
Association Between the Presence of Metabolic Comorbidities and Liver-Related Events in Patients With Chronic Hepatitis B.
Clin Gastroenterol Hepatol. 2023 Nov;21(12):3089-3096.e1. doi: 10.1016/j.cgh.2023.03.024. Epub 2023 Mar 31.
3
Hepatocellular carcinoma risk in patients with chronic hepatitis B receiving tenofovir- vs. entecavir-based regimens: Individual patient data meta-analysis.
J Hepatol. 2023 Mar;78(3):534-542. doi: 10.1016/j.jhep.2022.12.007. Epub 2022 Dec 23.
4
Risk of Hepatocellular Carcinoma With Tenofovir vs Entecavir Treatment for Chronic Hepatitis B Virus: A Reconstructed Individual Patient Data Meta-analysis.
JAMA Netw Open. 2022 Jun 1;5(6):e2219407. doi: 10.1001/jamanetworkopen.2022.19407.
5
Lower risk of hepatocellular carcinoma with tenofovir than entecavir treatment in subsets of chronic hepatitis B patients: an updated meta-analysis.
J Gastroenterol Hepatol. 2022 May;37(5):782-794. doi: 10.1111/jgh.15783. Epub 2022 Feb 7.
6
Antiviral therapy after curative treatment of hepatocellular carcinoma in patients with chronic hepatitis B infection: Is tenofovir or entecavir preferred?
Eur J Intern Med. 2021 Jul;89:27-29. doi: 10.1016/j.ejim.2021.05.003. Epub 2021 May 20.
7
Hepatocellular carcinoma incidence with tenofovir versus entecavir in chronic hepatitis B: a systematic review and meta-analysis.
Lancet Gastroenterol Hepatol. 2020 Dec;5(12):1039-1052. doi: 10.1016/S2468-1253(20)30249-1. Epub 2020 Sep 30.
8
Tenofovir Treatment Has Lower Risk of Hepatocellular Carcinoma than Entecavir Treatment in Patients with Chronic Hepatitis B: A Systematic Review and Meta-Analysis.
Liver Cancer. 2020 Aug;9(4):468-476. doi: 10.1159/000507253. Epub 2020 May 5.
9
Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B.
J Hepatol. 2020 Nov;73(5):1037-1045. doi: 10.1016/j.jhep.2020.06.011. Epub 2020 Jun 16.
10
Effects of Tenofovir vs Entecavir on Risk of Hepatocellular Carcinoma in Patients With Chronic HBV Infection: A Systematic Review and Meta-analysis.
Clin Gastroenterol Hepatol. 2021 Feb;19(2):246-258.e9. doi: 10.1016/j.cgh.2020.05.008. Epub 2020 May 11.
Zotero 插件